Syngene International Ltd

Q3 FY26Healthcare Services

Syngene International Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹407

Market cap₹16.4K Cr

P/E55.5

Updated23 Aug 2026

Read4 min read

The short version

Syngene expects the single large molecule product impact to continue through FY26 Q4 and into a couple of quarters in FY27 before it plays out. Syngene expects the single large molecule product impact to continue into FY27 but to play out over the next few quarters.

From Syngene International Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Syngene expects the single large molecule product impact to continue through FY26 Q4 and into a couple of quarters in FY27 before it plays out.
Excluding this one-off headwind, the rest of the business is growing steadily at high single-digit to low double-digit rates (constant currency).
Growth is broad-based across segments: research services (chemistry, biology, translational science, clinical) and CDMO (small and large molecules).
Capacity utilization improvements are underway in CDMO facilities in Bangalore, Mangalore, and Bayview (US), with early encouraging signs but still below expectations.
Management is focused on diversifying the business to reduce reliance on single large products and accelerating pipeline fill and capacity utilization to drive mid-to-long-term growth.
Formal guidance for FY27 will be provided after Q4 results, with qualitative confidence in improving trends.
Ongoing investments in capabilities and technologies, including AI and automation, support future growth.

Profitability & Margins

Syngene expects the single large molecule product impact to continue into FY27 but to play out over the next few quarters.
Excluding this impact, the rest of the business is growing steadily at high single-digit to low double-digit growth in constant currency.
The company is focused on accelerating growth across both CRO and CDMO segments by strengthening pipelines and capacity utilization.
Investments continue in capabilities and capacity expansion (e.g., Bangalore biologics, Bayview US facility), digital automation, and new technologies.
Formal guidance for FY27 will be provided after Q4 results, but management is optimistic about mid-term prospects due to ongoing R&D outsourcing trends.
Operating EBITDA margins are guided at around 22-23% for FY26, with no specific margin forecast for FY27 yet.
Profit growth and EPS improvement depend on mitigating large product headwinds and ramping up diversified revenues across platforms.

See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Syngene invested approximately $9 million in CAPEX during Q3 FY26.
Around 50% of CAPEX was for research services, including capability builds such as DMPK biology, ADC labs, and dedicated centers.
Approximately 35% was spent in the CDMO business on a new commercial-scale facility for liquid-filled hard gelatin capsules, integration of the Bayview facility (US biologics), and modifications to Unit-3.
Remaining CAPEX was directed toward digitization, automation, and common infrastructure.
The Bayview biologics facility in the US has completed process and equipment validation, with hiring underway to support operations as planned.
Overall CAPEX guidance for the full year is estimated at around $45 million.
Continued strategic investments are focused on expanding capabilities and capacity, including chemistry, biology, translational sciences, and clinical trials, to drive growth and diversify the business.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the provided document.
Syngene International Limited continues to invest in the business through internal cash flows, maintaining a strong balance sheet.
CAPEX for the year is estimated to be around $45 million, funded internally to enhance capabilities and capacities.
The company focuses on disciplined investments in technology, AI, and new capacities without indicating the need for external fundraising at this time.

See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention current or expected order book or pending orders for Syngene International Limited.
However, it highlights ongoing efforts to build and strengthen the business pipeline across research services and CDMO, indicating a focus on increasing capacity utilization at facilities in Bangalore, Mangalore, and Bayview (US).
Early encouraging signs of business traction and pipeline building are mentioned for both small and large molecule manufacturing operations.
The company is working on diversifying its portfolio to reduce exposure to single large products and build multiple large client relationships.
There is an ongoing dialogue with collaborators, like Zoetis, to explore incremental opportunities.
The Bayview biologics facility in the US is nearing operationalization, expected to support future order fulfillment.
Overall, the company expresses confidence in its pipeline and potential to accelerate growth, but no specific order book figures are provided.

Syngene International Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹148 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Syngene Intl.'s management said in earlier quarters

Others in Healthcare Services this season

Vijaya Diagnost. (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
Rainbow Child. (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

Compare:vs Apollo Hospitals vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Syngene International Ltd Q3 FY26 results?

What is Syngene International Ltd share price analysis?

Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.

Is Syngene International Ltd planning capital expenditure?

Syngene invested approximately $9 million in CAPEX during Q3 FY26.

Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.